Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
European Journal of Internal Medicine|August 16, 2003
Primary aortic sarcoma with widespread vascular embolic metastasesAlfonso Sánchez-Muñoz, Ricardo Hitt, Vivian Artiles, et al.European Journal of Cancer (Oxford, England : 1990)|February 5, 2005
Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapyRicardo Hitt, Eva Ciruelos, María L Amador, et al.Cancer|December 6, 2005
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckRicardo Hitt, Maria L Amador, Miguel Quintela-Fandino, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapyMiguel Quintela-Fandino, Ricardo Hitt, Pedro P Medina, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 4, 2009
Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcomaEnrique González-Billalabeitia, Ricardo Hitt, Jesús Fernández, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapyJan B Vermorken, José Trigo, Ricardo Hitt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neckJosé Baselga, José M Trigo, Jean Bourhis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell supportMiguel Quintela-Fandino, Joaquín Martínez López, Ricardo Hitt, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancerMaria Rodriguez-Pinilla, Jose L Rodriguez-Peralto, Ricardo Hitt, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer groupPierre Blanchard, Jean Bourhis, Benjamin Lacas, et al.Pageof 3